Success Metrics

Clinical Success Rate
82.8%

Based on 587 completed trials

Completion Rate
83%(587/709)
Active Trials
222(20%)
Results Posted
55%(324 trials)
Terminated
122(11%)

Phase Distribution

Ph phase_3
245
22%
Ph early_phase_1
12
1%
Ph not_applicable
34
3%
Ph phase_2
559
50%
Ph phase_4
7
1%
Ph phase_1
268
24%

Phase Distribution

280

Early Stage

559

Mid Stage

252

Late Stage

Phase Distribution1125 total trials
Early Phase 1First-in-human
12(1.1%)
Phase 1Safety & dosage
268(23.8%)
Phase 2Efficacy & side effects
559(49.7%)
Phase 3Large-scale testing
245(21.8%)
Phase 4Post-market surveillance
7(0.6%)
N/ANon-phased studies
34(3.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.7%

587 of 746 finished

Non-Completion Rate

21.3%

159 ended early

Currently Active

222

trials recruiting

Total Trials

1,128

all time

Status Distribution
Active(238)
Completed(587)
Terminated(159)
Other(144)

Detailed Status

Completed587
unknown143
Terminated122
Recruiting113
Active, not recruiting109
Withdrawn37

Development Timeline

Analytics

Development Status

Total Trials
1128
Active
222
Success Rate
82.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 112 (1.1%)
Phase 1268 (23.8%)
Phase 2559 (49.7%)
Phase 3245 (21.8%)
Phase 47 (0.6%)
N/A34 (3.0%)

Trials by Status

suspended10%
enrolling_by_invitation10%
not_yet_recruiting151%
terminated12211%
unknown14313%
withdrawn373%
active_not_recruiting10910%
completed58752%
recruiting11310%

Recent Activity

Clinical Trials (1,128)

Showing 20 of 1,128 trialsScroll for more
NCT02153580Phase 1

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Active Not Recruiting
NCT06406465Phase 2

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Recruiting
NCT05675410Phase 3

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Recruiting
NCT07155174Phase 2

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Recruiting
NCT04803201Phase 2

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Recruiting
NCT06172296Phase 3

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Recruiting
NCT02595424Phase 2

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Active Not Recruiting
NCT04231877Phase 1

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Active Not Recruiting
NCT03407144Phase 2

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

Active Not Recruiting
NCT02166463Phase 3

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Active Not Recruiting
NCT04092283Phase 3

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Active Not Recruiting
NCT02337985Phase 1

Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma

Active Not Recruiting
NCT07227597Phase 1

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

Recruiting
NCT07850973Phase 1

Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors

Not Yet Recruiting
NCT01555710Phase 3

Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)

Terminated
NCT06077500Phase 1

DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

Active Not Recruiting
NCT07843940Phase 1

A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

Not Yet Recruiting
NCT05058651Phase 2

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Recruiting
NCT07472517Phase 3

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

Recruiting
NCT07847190Phase 2

Paclitaxel-Bleomycin/Etoposide/Cisplatin vs Bleomycin/Etoposide/Cisplatin in Poor-prognosis Non-seminomatous Germ Cell Tumors (NSGCT) and Unfavorable Tumor Marker Decline: Randomized Phase II Trial

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
1,128